FDA Approves Moderna's Updated COVID Boosters; $2B Convertible Offering Announced
MRNA has more than doubled off its 52-week low of $22.28.
Summary
The FDA approved Moderna's 2026-2027 COVID boosters Spikevax and mNEXSPIKE targeting JN.1 XFG, with doses shipping in coming days. This follows the August 6 approval of its flu vaccine and the August 19 intismeran melanoma data that sent shares up 177%. Separately, Moderna plans a $2.0B convertible note offering due 2032 (plus $300M option) to fund oncology and corporate purposes. The booster approval secures near-term revenue, while the offering adds dilution risk but strengthens the balance sheet. Watch for global booster approvals and pricing of the convertible notes.
At the time of this announcement, MRNA was trading at $141.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57B. The 52-week trading range was $22.28 to $176.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.